KPTIKaryopharm Therapeutics IncSigning up patients
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
Multiple Myeloma, Refractory
1Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.3
6 insiders sold shares within a month
Since May 14, 2026 · was worth 10, fading over time
Worry score1
Score over time
- Stage
- Phase 2
- Patients
- 127 (planned)
- Started
- Jul 1, 2020
- Main results expected
- Jan 2028
- Fully finished
- Jan 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Response Rate (ORR)
Measured over: From the date of randomization up to death (approximately 60 months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 1.3, since 2026-05-14, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04414475 · record last updated 2026-10-29 · checked 2026-11-09 15:47 UTC